Protara Therapeutics, Inc. (TARA)

3.2400 +0.2400 (+8.00%) 收市：04:00PM EDT

Protara Therapeutics, Inc.

345 Park Avenue South
3rd Floor
New York, NY 10010
United States
646 844 0337
https://www.protaratx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 26

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Jesse Shefferman	CEO, President & Director	1.02M	無	1972
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.	Co-Founder, Senior VP & Chief Scientific Operations Officer	694.16k	無	1981
Mr. Patrick Fabbio M.B.A.	Chief Financial Officer	696.62k	無	1968
Ms. Hannah Fry	VP, Principal Accounting Officer & Controller	無	無	1991
Ms. Justine O'Malley	Senior Vice President of Investor Relations & Corporate Affairs	無	無	無
Ms. Mary J. Grendell	General Counsel & Corporate Secretary	無	無	無
Dr. Jathin Bandari M.D.	Executive Officer	687.86k	無	1988

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

公司管治

截至 無 止，Protara Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。